Alexander J. Denner Buys 431,000 Shares of The Medicines Company (MDCO) Stock

The Medicines Company (NASDAQ:MDCO) Director Alexander J. Denner bought 431,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was bought at an average cost of $33.89 per share, for a total transaction of $14,606,590.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

NASDAQ MDCO traded down $0.43 during trading on Wednesday, reaching $33.25. 1,171,420 shares of the company’s stock were exchanged, compared to its average volume of 1,091,669. The company has a market cap of $2.53 billion, a PE ratio of -11.43 and a beta of 1.36. The Medicines Company has a fifty-two week low of $16.69 and a fifty-two week high of $41.57.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Thursday, April 25th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.09). During the same quarter in the prior year, the business earned ($0.76) earnings per share. The company’s revenue was down 100.0% compared to the same quarter last year. Equities analysts forecast that The Medicines Company will post -2.74 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Oregon Public Employees Retirement Fund acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $25,000. Bank of Montreal Can grew its position in shares of The Medicines by 31.9% in the fourth quarter. Bank of Montreal Can now owns 3,139 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares during the last quarter. First Mercantile Trust Co. grew its position in shares of The Medicines by 21.6% in the fourth quarter. First Mercantile Trust Co. now owns 3,965 shares of the company’s stock valued at $76,000 after purchasing an additional 705 shares during the last quarter. Advisory Services Network LLC grew its position in shares of The Medicines by 196.7% in the fourth quarter. Advisory Services Network LLC now owns 4,450 shares of the company’s stock valued at $85,000 after purchasing an additional 2,950 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of The Medicines by 61.1% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,990 shares of the company’s stock valued at $125,000 after purchasing an additional 2,651 shares during the last quarter.

A number of equities analysts have weighed in on the company. Robert W. Baird assumed coverage on The Medicines in a research report on Wednesday, March 27th. They set an “outperform” rating and a $80.00 price target on the stock. BidaskClub raised The Medicines from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Roth Capital assumed coverage on The Medicines in a research report on Thursday, March 21st. They set a “buy” rating and a $75.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $90.00 price target (up previously from $85.00) on shares of The Medicines in a research report on Friday, April 26th. Finally, B. Riley set a $38.00 price target on The Medicines and gave the stock a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The Medicines presently has an average rating of “Buy” and an average price target of $62.00.

COPYRIGHT VIOLATION WARNING: “Alexander J. Denner Buys 431,000 Shares of The Medicines Company (MDCO) Stock” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/22/alexander-j-denner-buys-431000-shares-of-the-medicines-company-mdco-stock.html.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.

Featured Article: Beta

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.